Primary Testing For Lung Cancer Patient

Assists Newly Diagnosed Lung Cancer Patients to Rapidly Identify First-Line Targeted Therapy Opportunities

Lung cancer has the highest mortality rate among all cancer types. In recent years, the rapid development of drugs has provided lung cancer patients with the opportunity to achieve better treatment results. Patients with newly diagnosed NSCLC can consider using ACTLung™ to identify opportunities focusing targeted drugs.


A Precise Choice for Cancer Genomic Profiling

ACTLung™ is a next-generation sequencing (NGS)-based assay, which sequences 13 actionable genes and 8 fusion genes transcripts simultaneously from cancer specimens in our CAP-accredited laboratory. This assay is specifically designed for patients with lung cancer, providing tailored genomic profile and recommendations of targeted drugs approved by USFDA.

ACTLung™ performs various genetic variation analyses. In addition to single nucleotide variation (SNV) and small insertion/ deletion (InDel), it provides fusion gene detection for more precise implications.

Hallmarks of ACTLung™

  1. Drug-Target-Based Panel
    Sequences 13 actionable genes and 8 fusion genes with genetic alterations.

  2. Tailored Drug Options
    Analyses single nucleotide variation (SNV), small insertion/deletion (InDel) and fusion genes to provide tailored drug options.

  3. Short Turnaround Time
    Provides professional solutions within 8 working days (starting from the date of receipt of approved samples at our CAP-accredited laboratory).

  4. Bioinformatics Analysis Based on International Databases
    Extracts up-to-date information from international databases, such as gnomAD, 1000 Genome, ClinVar, COSMIC, as well as ACT Genomics' in-house ethnographic database, to provide relevant interpretation and useful insights on the variants identified.

  5. Clear and Detailed Medical Reporting
    The report provides recommendations in accordance with the latest ACMG Guidelines and AMP Guidelines, as well as other relevant information such as disease risk based on the currently available clinical literature.

  6. Quality Guarantee
    All tests carried out by ACT Genomics are conducted in a CAP-certified laboratory, which has also earned the LDTS (Laboratory Developed Tests and Services) certification by the Taiwan FDA.

Summary of ACTLung™

  1. For Solid Tumors
    Selects suitable treatment for newly diagnosed patients based on actionable genetic mutations.

  2. Precise Reporting
    Considers targeted therapies and hormonal therapies approved by US FDA or in clinical trials.

Technical Specifications


Next Generation Sequencing (NGS)

13 actionable genes


Sequencing Mean Depth

≥ 800 x


Specimen Requirements*

Tumor tissue (FFPE)

*refer to our specimen instructions